Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucid-21-302 MAD study in healthy adults
NCT06595706Phase 1Completed
- Sponsor
- Huge Biopharma Australia
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing Lucid-21-302 with Placebo (2 arms). Primary endpoints: Incidence, severity and relationship of Adverse Events (AEs) up to 15 days, Incidence of Serious AEs (SAEs) and suspected unexpected SAEs up to 15 days and 16 more. Started Sep 2024; status: completed.
02
Drugs
Lucid-MS
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06595706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06595706.